查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840747

鼻腔給藥和疫苗市場（按藥物類型、劑型、裝置類型、劑量、應用和最終用戶分類）－2025-2032年全球預測

Intranasal Drug & Vaccine Delivery Market by Drug Type, Formulation Type, Device Type, Dosage, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，鼻腔給藥和疫苗輸送市場規模將達到 796.1 億美元，複合年成長率為 6.09%。

關鍵市場統計數據
基準年 2024 495.9億美元
預計年份：2025年 524.3億美元
預測年份 2032 796.1億美元
複合年成長率 (%) 6.09%

權威的鼻腔治療藥物和疫苗說明，概述了科學前景、實際限制以及產品開發的戰略考量

鼻腔給藥已成為製劑科學、器材工程和以病人為中心的醫療理念交叉領域的重要策略性給藥方式。過去十年，黏膜免疫學、製劑穩定劑和精準給藥裝置的進步，使鼻腔給藥從小眾替代方案轉變為治療藥物和疫苗的主流選擇。隨著臨床研發管線的成熟，製藥、生物技術和醫療器材製造領域的相關人員正在調整其臨床開發計劃、監管策略和商業策略，以充分體現鼻腔給藥的獨特優勢和限制。

本導言將鼻腔給藥置於更廣泛的治療生態系中，重點介紹其優勢，包括某些分子可快速全身吸收、非侵入性給藥可提高患者依從性，以及能夠誘導針對呼吸道病原體的強效粘膜免疫反應。同時，本導言也指出了持續影響專案設計的許多技術難題，例如製劑的黏度和穩定性、裝置引起的沉積差異、多重藥物合併治療與單一藥物治療的劑量重複性，以及複雜生技藥品的冷鏈管理等。透過闡述機會與挑戰，本部分旨在幫助讀者理解監管溝通、生產低溫運輸和市場推廣計畫等策略性權衡。

本執行摘要從基礎科學入手，探討了重塑格局的關鍵變化，分析了不斷演變的貿易政策和供應鏈之間的相互聯繫，並將市場細分和區域動態轉化為對開發商和投資者的實際商業性影響。

技術、臨床和商業方面的關鍵因素正在匯聚，使鼻腔給藥成為疫苗和標靶治療的策略性給藥方式。

鼻腔給藥正受到技術、臨床和商業性因素共同作用的重塑。首先，製劑科學的進步使得穩定的液體和粉末製劑得以實現，從而擴大了可透過鼻粘膜遞送的生物活性分子種類。同時，從精密霧化器到低變異性定量吸入器，裝置工程的進步正在降低劑量不確定性並提高藥物靶向沉積率。

臨床證據也正在改變人們的認知。經鼻吸入型疫苗候選藥物的新興免疫抗原性數據表明，鼻腔疫苗可能增強針對呼吸道病原體的黏膜免疫力，從而補充腸外疫苗引起的全身免疫反應。鼻腔給藥途徑正被探索用於治療神經系統疾病和疼痛管理，它能夠快速使藥物作用於中樞神經系統，同時最大限度地減少全身副作用。在商業性，患者對非侵入性給藥方式的偏好以及居家照護帶來的營運效率，正迫使支付方和醫療服務提供者重新思考處方分配和門診治療路徑。總而言之，這些進展正在改變專案的優先順序，促進製劑和器械專家之間的夥伴關係，並推動供應鏈重組，以支持對低溫運輸敏感的生技藥品和敏感器械組件的採購。

2025 年關稅格局如何重塑鼻內給藥價值鏈的採購、生產在地化和策略供應商多元化？

2025年，美國徵收的關稅累積效應為全球鼻用藥物及給藥裝置的供應鏈帶來了顯著的複雜性。對進口零件（例如霧化器專用聚合物、霧化器精密金屬零件以及某些原料藥前驅物）徵收的關稅，加劇了到岸成本的波動，促使採購團隊重新評估採購區域。製造商面臨權衡取捨：是自行承擔增加的成本、將成本轉嫁給下游環節，還是投資於短期內實現生產和組裝的本地化，以保護利潤並規避關稅的影響。

這些壓力對監管和策略規劃產生了連鎖反應。研發團隊在供應商合約中加入了緊急採購條款，並加快了備選供應商的資格審核，以確保臨床試驗的連續性。對於依賴複雜供應鏈取得mRNA組分和低溫運輸耗材的疫苗研發企業而言，關稅環境促使獎勵將生產營運集中在本國或盟國境內，以降低邊境風險。同時，合約研發受託製造廠商等服務提供者也透過擴大區域產能和提供考慮關稅因素的籌資策略來應對，從而最大限度地減少營運中斷。

展望未來，關稅驅動的成本動態正在再形成設備選擇和給藥方式的決策。當關稅影響到初級包裝和設備組件時，企業正在權衡重新配製單劑量製劑所需的資本密集度，以及多劑量給藥系統的物流複雜性和潛在成本優勢。最終，關稅環境正在加速戰略本地化，將供應商多元化提升為董事會層面的關注點，並鼓勵企業主動參與政策制定，為生命科學關鍵組件尋求豁免和優惠分類。

詳細的細分分析揭示了藥物類別、製劑、器材、劑型、臨床用途和最終用戶特徵如何決定藥物開發策略。

深入分析鼻腔製劑的細分市場，可以發現其發展機會和技術要求多種多樣。從藥物類型來看，該領域涵蓋多種子類別，例如鎮痛藥（非鴉片類和鴉片類）、抗組織胺、類固醇、疫苗、去活化疫苗、減毒疫苗以及基於mRNA的候選疫苗。鎮痛藥強調快速吸收和良好的耐受性，抗組織胺藥物和類固醇則優先考慮局部療效和粘膜滯留，而疫苗則需要穩定性、佐劑相容性和抗原性保持能力。凝膠製劑可延長藥物與黏膜的接觸時間，液體製劑可與現有的定量給藥裝置配合使用，而粉末製劑則具有耐熱性並簡化了低溫運輸物流。

裝置類型同樣重要：霧化器平台可實現適用於更廣泛粘膜覆蓋的細顆粒分散，而滴鼻劑雖然給藥簡單且成本低廉，但劑量精度有限。劑型選擇（多劑量或單劑量）不僅影響患者的便利性，也影響監管和防腐策略，進而影響保存期限和微生物安全性。過敏治療、荷爾蒙替代療法、神經系統疾病、疼痛管理、精神疾病和藥物傳遞——每種療法都有其獨特的臨床終點、真實世界中的依從性以及報銷方面的考慮。不同的終端使用者——居家醫療、醫院/診所和研究/學術機構——決定了部署模式、培訓要求和裝置穩健性規範。這些相互交織的細分維度共同決定了計畫的啟動/終止、臨床終點的最佳化以及最有可能提供穩定治療效果的裝置和製劑組合的選擇。

比較區​​域動態如何影響主要全球市場的監管方式、生產佈局和商業化策略

區域動態對發展重點、監管策略和商業化藍圖有顯著影響。在美洲，強大的臨床試驗基礎設施以及公共和私人機構對呼吸道疫苗和新型止痛藥製劑的大量投資，正推動著鼻內給藥創新技術的快速普及。關鍵市場的監管路徑強調可靠的臨床終點和上市後監測，這加速了證據的產生，但也要求及早規劃真實世界數據的收集和與支付方的溝通。同時，該地區的製造生態系統正日益轉向模組化設施設計和製造外包夥伴關係，以適應生物製藥和醫療器材的整合。

歐洲、中東和非洲地區（EMEA）的監管格局呈現出分散的特點，涉及多個司法管轄區，每個司法管轄區對器械-藥物組合應用和粘膜疫苗的臨床證據都有不同的要求。由於部分市場面臨物流挑戰，該地區對低溫運輸的粉末製劑表現出濃厚的興趣。該地區的相關人員通常優先考慮成本效益和公共衛生採購動態，這會影響商業性定價策略和可擴展疫苗宣傳活動的規劃。

亞太地區人口密度高、疾病負擔多樣，且生物製藥生產能力快速擴張，這為大規​​模疫苗推廣和主導的鼻內給藥療法的引入提供了極具吸引力的案例研究。區域性的生產激勵措施和積極的公私合作有助於加速臨床項目，而該地區在醫療器材組件製造方面的供應鏈優勢則為垂直整合提供了機會。總而言之，這些地區在市場進入、夥伴關係模式和監管路徑方面呈現出差異化的特點，必須與製造地選址和分銷模式相匹配。

製藥創新者、器材設計者、合約研發生產機構 (CDMO) 和生物技術新參與企業之間的策略行動和競爭動態將決定鼻腔給藥領域的領導地位。

產業主要參與者包括大型跨國製藥公司、專業設備製造商、合約研發受託製造廠商 ( CDMO) 以及專注於黏膜免疫學和製劑科學的敏捷生物技術創新者。領先企業正在採取幾項通用的策略性舉措：在研發管線早期整合器材和製劑開發，以降低後期相容性風險；與學術中心建立多學科合作關係，以充分利用對黏膜免疫機制的深入了解；以及投資於可擴展的液體和粉末疫苗填充和包裝能力。此外，服務供應商透過提供滿足器械-藥物組合產品獨特需求的全面監管和品質服務包來脫穎而出。

競爭對手正致力於圍繞新型給藥機制、黏合劑化學和霧化器技術培育智慧財產權，部分企業也尋求適用於止痛藥、荷爾蒙療法和疫苗建構的平台策略。以病人為中心的設計——例如給藥便利性、劑量精準性和便攜性——正成為衡量商業性成功的關鍵指標，尤其是在居家醫療日益普及的情況下。最後，策略性併購和授權協議經常被用於整合製劑專業知識和市場推廣能力，從而加速臨床應用，同時將研發風險分擔給合作夥伴。

為加速臨床和商業性成功，提出切實可行的策略建議，以協調設備共同開發、供應鏈韌性、配方選擇和證據產生。

產業領導者應採取多管齊下的方法，將科學嚴謹性與商業性實用性結合。首先，從一開始就優先考慮一體化的設備和配方開發，以避免可能延誤監管申報的下游相容性問題。其次，拓展關鍵零件的供應商網路，並尋找本地製造合作夥伴，以降低關稅和地緣政治風險，同時透過平行工藝驗證合格二級供應商，從而確保臨床實驗的連續性。

第三，由於製劑選擇直接影響低溫運輸負擔、分銷策略和病患接受度，我們將投入資源進行一項完善的穩定性研究項目，並行評估液體、凝膠和粉末三種製劑方案。第四，我們將採用適應性臨床設計和真實世界證據策略，以明確疫苗在黏膜和全身終點以及治療適應症方面的動態結果。第五，我們將與學術界、醫療器材專家和合約研發生產機構（CDMO）建立策略聯盟，以加速平台成熟並共用研發風險。最後，我們將儘早納入患者和醫護人員體驗指標，以指導器械的人體工學設計和培訓材料，並確保在居家醫療和門診病人環境中的商業性部署得到清晰的使用指南和依從性監測途徑的支持。

採用綜合研究途徑，結合一手訪談、技術文獻綜述、法規分析和三角驗證，以檢驗可用於鼻腔給藥計畫的實際可行的見解。

本執行摘要的研究整合了第一手訪談、二手文獻、監管指南和技術檢驗，旨在建構對鼻腔給藥的全面、多角度的理解。第一手研究包括對製劑科學家、器材工程師、法規事務專業人員、採購負責人和臨床終端使用者進行結構化訪談，以了解實際限制、推廣應用促進因素和新興的臨床優先事項。二級資訊來源，包括關於粘膜免疫學的同行評審文獻、關於組合藥物的官方監管指南以及關於噴霧和粉劑給藥技術的技術白皮書，有助於將第一手研究成果置於更廣闊的背景中進行解讀。

透過將訪談結果與監管文件和設備製造商的技術規格進行交叉比對，實施了資料三角驗證，以確保所宣稱的設備性能與觀察到的臨床需求相符。品質保證措施包括專家評審小組和供應鏈假設的情境壓力測試，特別關注關稅和本地化影響。調查方法的局限性包括：雖然這種方法強調深度和交叉檢驗，但可能無法充分體現具體的合約和獨特的生產細節。儘管如此，該調查方法仍為鼻用藥物產品生命週期中的策略決策提供了全面、實證的基礎。

一份權威的綜合報告，重點闡述了將鼻內創新轉化為臨床和商業性可行的產品所需的實際必要條件和戰略路徑。

鼻腔給藥正處於策略曲折點，科學前景與實際應用挑戰並存。製劑化學和裝置精度的進步正在拓展該方法在疫苗和各種治療適應症中的效用，而關稅調整和供應鏈中斷則凸顯了籌資策略和生產佈局決策的重要性。細分市場分析表明，成功取決於對藥物類型、製劑形式、裝置選擇、給藥方式、預期用途和最終用戶情況的精心客製化。

這意味著要儘早整合設備和配方，在必要時建立具有韌性的社區供應鏈，並關注黏膜和真實世界療效終點，從而產生能夠引起監管機構和支付方共鳴的證據。在這些領域取得卓越成效，將使那些能夠把鼻科科學的最新進展轉化為患者和醫療保健系統可及且有效的產品的領導者脫穎而出。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 用於延長鼻腔藥物滯留時間的黏膜附著性聚合物系統的研究進展
  • 利用氣溶膠奈米載體增強經鼻給藥的腦部標靶遞送
  • 整合3D列印技術製造個人化滴鼻藥劑
  • 鼻腔給藥減毒活病毒疫苗的臨床進展表明，其能增強黏膜免疫力。
  • 一種採用速效小分子製劑的新型經鼻偏頭痛治療方法
  • 鼻用胰島素噴劑擴大臨床試驗範圍，用於治療神經退化性疾病
  • 利用先進的噴霧冷凍乾燥技術大規模生產乾粉經鼻吸入型疫苗
  • 製藥和醫療設備製造商攜手合作，最佳化鼻噴霧給藥系統
  • 採用即時成像技術監測鼻內沉積和吸收情況

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按藥物類型分類的鼻腔給藥和疫苗市場

  • 止痛藥
    • 非鴉片類藥物
    • 鴉片類藥物
  • 抗組織胺藥
  • 類固醇
  • 疫苗
    • 去活化疫苗
    • 減毒活疫苗
    • 基於mRNA的疫苗

9. 按劑型分類的鼻腔藥物和疫苗遞送市場

  • 凝膠配方
  • 液體配方
  • 粉末製劑

第10章 依設備類型分類的鼻腔藥物和疫苗傳輸市場

  • 霧化器
  • 鼻滴管
  • 鼻噴劑

11. 按劑量分類的鼻腔給藥和疫苗市場

  • 多劑量
  • 單一劑量

第12章 按應用分類的鼻腔藥物和疫苗遞送市場

  • 過敏治療
  • 荷爾蒙補充療法
  • 神經系統疾病
  • 疼痛管理
  • 精神疾病
  • 治療性藥物遞送

第13章 依最終用戶分類的鼻腔藥物和疫苗遞送市場

  • 居家照護
  • 醫院和診所
  • 研究和學術機構

第14章 各地區鼻腔藥物及疫苗傳輸市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 按組別分類的鼻腔藥物和疫苗遞送市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國鼻腔給藥及疫苗市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Altimmune, Inc.
    • AptarGroup, Inc.
    • AstraZeneca PLC
    • Bausch Health Companies Inc.
    • Bayer AG
    • Becton, Dickinson, and Company
    • Bharat Biotech Ltd.
    • Boehringer Ingelheim International GmbH.
    • Catalent, Inc
    • DCA Design International Limited
    • Emergent BioSolutions Inc.
    • GlaxoSmithKline PLC
    • Hovione Limited
    • Impel Pharmaceuticals LLC.
    • Indivior PLC
    • Intersect ENT by Medtronic plc
    • Intertek Group PLC
    • Johnson & Johnson Services, Inc.
    • Kindeva Drug Delivery LP
    • Merck & Co., Inc.
    • Neurelis, Inc.
    • Novartis AG
    • OptiNose, Inc.
    • Pfizer Inc.
    • Recipharm AB.
    • Sanofi SA
    • Teleflex Incorporated
    • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-A339DAEFA961

The Intranasal Drug & Vaccine Delivery Market is projected to grow by USD 79.61 billion at a CAGR of 6.09% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 49.59 billion
Estimated Year [2025] USD 52.43 billion
Forecast Year [2032] USD 79.61 billion
CAGR (%) 6.09%

An authoritative orientation to intranasal therapeutics and vaccines that frames scientific promise, practical constraints, and strategic considerations for product development

Intranasal delivery has emerged as a strategic modality at the intersection of drug formulation science, device engineering, and patient-centric care. Over the past decade, advances in mucosal immunology, formulation stabilizers, and precision dosing devices have repositioned the nasal route from a niche alternative to a mainstream consideration for both therapeutic drugs and vaccines. As clinical pipelines mature, stakeholders across pharmaceutical, biotech, and device manufacturing spheres are recalibrating clinical development plans, regulatory approaches, and commercial strategies to reflect the distinctive advantages and constraints of the nasal route.

This introduction situates intranasal delivery within the broader therapeutic ecosystem by highlighting its appeal: rapid systemic absorption for certain molecules, noninvasive administration that enhances patient adherence, and the potential to elicit robust mucosal immune responses for respiratory pathogens. At the same time, it recognizes the technical hurdles that continue to shape program design, including formulation viscosity and stability, device-driven deposition variability, dose reproducibility in multi-dose versus unit-dose formats, and cold-chain considerations for complex biologics. By framing both the opportunities and constraints, this section prepares readers to appreciate the strategic trade-offs that follow in regulatory engagement, manufacturing investments, and market access planning.

Transitioning from the foundational science to practical deployment, the rest of this executive summary unpacks the major shifts reshaping the landscape, explores how evolving trade policies intersect with supply chains, and maps segmentation and regional dynamics to pragmatic commercial implications for developers and investors.

Key converging technological, clinical, and commercial drivers that are transforming intranasal delivery into a strategic modality for vaccines and targeted therapeutics

The intranasal landscape is being reshaped by converging technological, clinical, and commercial forces that collectively elevate the modality beyond incremental improvement to a transformative pathway for specific indications. First, formulation science has advanced to allow stable liquid and powder presentations that extend the range of biologically active molecules deliverable via the nasal mucosa; innovations in mucoadhesives and permeation enhancers are enabling higher bioavailability for peptides and select biologics. Concurrently, device engineering developments-from precision atomizers to low-variability metered sprays-are reducing dosing uncertainty and improving targeted deposition, which in turn influences clinical design and regulatory strategy.

Clinical evidence has also shifted perceptions. Emerging immunogenicity data for intranasal vaccine candidates suggest the potential for stronger mucosal immunity against respiratory pathogens, complementing systemic responses elicited by parenteral vaccines. For therapeutic agents addressing neurological conditions or pain management, intranasal routes are being explored for their ability to enable rapid CNS exposure while minimizing systemic side effects. Commercially, patient preference for noninvasive administration and the operational efficiencies of homecare delivery are prompting payers and providers to reassess formulary placement and outpatient treatment pathways. Taken together, these developments are transforming program prioritization, catalyzing partnerships across formulation and device specialists, and prompting supply-chain reconfiguration to support cold-chain sensitive biologics and precision device-component sourcing.

How the 2025 tariff landscape has reshaped procurement, manufacturing localization, and strategic supplier diversification across the intranasal delivery value chain

In 2025, the cumulative effect of tariffs imposed by the United States introduced material complexities into global supply chains for intranasal pharmaceuticals and delivery devices. Tariffs on imported components, including specialized polymers for sprayers, precision metal parts for atomizers, and certain active pharmaceutical ingredient precursors, increased landed cost variability and prompted procurement teams to re-evaluate sourcing geographies. Manufacturers faced trade-offs between absorbing incremental costs, passing them downstream, or investing in near-term localization of manufacturing and assembly to preserve margin and avoid tariff exposure.

These pressures have had ripple effects on regulatory and strategic planning. Development teams incorporated contingency sourcing clauses into supplier agreements and accelerated qualification of alternate vendors to maintain clinical trial continuity. For vaccine developers reliant on complex supply chains for mRNA components and cold-chain consumables, the tariff environment intensified incentives to consolidate manufacturing steps domestically or within allied jurisdictions to mitigate border risk. At the same time, service providers such as contract development and manufacturing organizations responded by expanding regional capacity and offering tariff-aware sourcing strategies to minimize operational disruption.

Looking ahead, tariff-driven cost dynamics are reshaping decisions about device choice and dosage format. Companies are weighing the capital intensity of retooling for unit-dose formats against the logistical complications and potential cost advantages of multi-dose systems when tariffs affect primary packaging or device components. Ultimately, the tariff environment has accelerated strategic localization, elevated supplier diversification as a board-level concern, and encouraged preemptive policy engagement to seek exemptions or favorable classifications for life-science critical components.

In-depth segmentation insights revealing how drug class, formulation, device, dosage format, clinical application, and end-user profile jointly determine development strategies

A granular view of segmentation reveals the heterogeneity of opportunity and technical requirements across intranasal programs. When examining drug type, the field encompasses Analgesics-studied across Non-opioids and Opioids-alongside Antihistamines, Steroids, and Vaccines with subcategories that include Inactivated Vaccines, Live Attenuated Vaccines, and mRNA-based Vaccine candidates. Each class imposes distinct formulation imperatives: analgesic molecules emphasize rapid absorption profiles and tolerability, antihistamines and steroids prioritize local effect and mucosal retention, while vaccines demand stability, adjuvant compatibility, and preservation of antigenicity. Formulation type further differentiates development pathways, with Gel Formulations offering prolonged mucosal contact, Liquid Formulations supporting established metered-dosing devices, and Powder Formulations presenting options for thermostability and simplified cold-chain logistics.

Device type is equally determinative: Atomizer platforms enable fine-particle dispersion suitable for broader mucosal coverage; Nasal Droppers provide simple, low-cost administration but with limited dosing precision; Nasal Spray devices balance dose control with patient familiarity. Dosage format choices between Multi-dose and Unit-dose influence not only patient convenience but also regulatory and preservative strategies, impacting shelf life and microbiological safeguards. Application segmentation spans Allergy Treatment, Hormone Replacement, Neurological Conditions, Pain Management, Psychiatric Disorders, and Therapeutic Drug Delivery, each with unique clinical endpoints, real-world adherence profiles, and reimbursement considerations. End-user distinctions among Homecare, Hospitals & Clinics, and Research & Academic Institution determine deployment models, training requirements, and device robustness specifications. Together, these intersecting segmentation axes inform go/no-go decisions, optimization of clinical endpoints, and the selection of device-formulation pairings most likely to deliver consistent therapeutic outcomes.

Comparative regional dynamics that shape regulatory approaches, manufacturing footprints, and commercialization strategies across major global markets

Regional dynamics exert a powerful influence on development priorities, regulatory tactics, and commercialization roadmaps. In the Americas, strong clinical trial infrastructure and substantial private and public investment into respiratory vaccines and novel analgesic formulations drive rapid adoption of intranasal innovations. Regulatory pathways in major markets emphasize robust clinical endpoints and post-marketing surveillance, which accelerates evidence generation but requires early planning for real-world data capture and payer engagement. Meanwhile, manufacturing ecosystems in the region are increasingly geared towards modular facility designs and contract manufacturing partnerships to accommodate both biologics and device integration.

The Europe, Middle East & Africa landscape is characterized by regulatory fragmentation across multiple jurisdictions, each with nuanced expectations for device-drug combination submissions and clinical evidence for mucosal vaccines. This region sees pronounced interest in cold-chain independent formulations and powder formats, given logistical challenges in some markets. Stakeholders here often prioritize cost-effectiveness and public health procurement dynamics, which influences commercial pricing strategies and the design of scalable immunization campaigns.

Across the Asia-Pacific region, high population density, diverse disease burdens, and rapid expansions in biopharma manufacturing capacity create compelling case studies for scaled vaccine deployment and consumer-driven adoption of intranasal therapeutics. Local manufacturing incentives and active public-private alliances foster acceleration of clinical programs, while regional supply-chain strengths in device component production present opportunities for vertical integration. Taken together, these regions present differentiated pathways for market entry, partnership configuration, and regulatory sequencing that should be weighed against manufacturing footprint decisions and distribution models.

Strategic behaviors and competitive dynamics among pharmaceutical innovators, device designers, CDMOs, and biotech entrants that are defining leadership in intranasal delivery

Key industry participants span large multinational pharmaceutical developers, specialized device manufacturers, contract development and manufacturing organizations, and agile biotech innovators focusing on mucosal immunology and formulation science. Leading actors are pursuing several common strategic behaviors: integrating device and formulation development earlier in the pipeline to reduce late-stage compatibility risk, forming multi-disciplinary alliances with academic centers to leverage mechanistic mucosal immunity insights, and investing in scalable fill-finish capabilities that accommodate both liquid and powder vaccine formats. In addition, service providers are differentiating by offering combined regulatory and quality packages that reflect the unique demands of device-drug combination products.

Competitive dynamics emphasize IP cultivation around novel delivery mechanisms, mucoadhesive chemistries, and atomizer technologies, with a subset of players pursuing platform strategies that can be applied across analgesics, hormone therapies, and vaccine constructs. Investment in patient-centric design-ease of administration, dosing accuracy, and portability-has become a core metric for commercial success, particularly as homecare adoption rises. Finally, strategic M&A and licensing arrangements are frequently used to pair formulation expertise with route-to-market capabilities, enabling faster clinical translation while spreading development risk across partners.

Actionable strategic recommendations for aligning device co-development, supply-chain resilience, formulation choices, and evidence generation to accelerate clinical and commercial success

Industry leaders should adopt a multi-pronged approach that aligns scientific rigor with commercial pragmatism. First, prioritize integrated device and formulation development from the outset to avoid downstream compatibility issues that can delay regulatory submissions; early co-development reduces iteration cycles and supports cleaner clinical datasets. Second, diversify supplier networks for critical components and identify localized manufacturing partners to mitigate tariff and geopolitical risk, while simultaneously qualifying secondary vendors through parallel process validation to preserve trial continuity.

Third, invest in robust stability programs that evaluate liquid, gel, and powder options in parallel, because formulation choice directly influences cold-chain burden, distribution strategy, and patient acceptability. Fourth, pursue adaptive clinical designs and real-world evidence strategies that demonstrate both mucosal and systemic endpoints for vaccines and clear pharmacodynamic outcomes for therapeutic indications; this evidence will be pivotal for payers and public health purchasers. Fifth, cultivate strategic alliances across academia, device specialists, and CDMOs to accelerate platform maturation and share developmental risk. Finally, incorporate patient and provider experience metrics early to inform device ergonomics and training materials, ensuring that commercial rollout in homecare and outpatient settings is supported by clear usage guidance and adherence monitoring pathways.

Comprehensive research approach combining primary interviews, technical literature synthesis, regulatory analysis, and triangulation to validate actionable insights for intranasal programs

The research underpinning this executive summary synthesizes primary interviews, secondary literature, regulatory guidance, and technical validation to construct a robust, multi-dimensional understanding of intranasal delivery. Primary research included structured interviews with formulation scientists, device engineers, regulatory affairs professionals, procurement leads, and clinician end-users to capture practical constraints, adoption drivers, and emergent clinical priorities. Secondary sources comprised peer-reviewed literature on mucosal immunology, public regulatory guidance on combination products, and technical white papers on spray and powder delivery technologies to contextualize primary insights.

Data triangulation was implemented by cross-referencing interview findings with regulatory documentation and technical specifications from device manufacturers, ensuring consistency between claimed device performance and observed clinical requirements. Quality assurance steps included expert review panels and scenario stress-testing of supply-chain assumptions, particularly in relation to tariff and localization implications. Limitations of the methodology are acknowledged: rapidly evolving clinical data and commercial agreements can introduce change after the research cut-off, and while the approach emphasizes depth and cross-validation, specific contractual or proprietary manufacturing details may not be fully represented. Nonetheless, the methodology provides a comprehensive, evidence-based foundation for strategic decision-making across the intranasal product lifecycle.

A decisive synthesis underscoring the practical imperatives and strategic pathways required to translate intranasal innovations into clinically and commercially viable products

Intranasal delivery sits at a strategic inflection point where scientific potential meets pragmatic deployment challenges. Advances in formulation chemistry and device precision have expanded the modality's utility across vaccines and a range of therapeutic indications, while tariff shifts and supply-chain disruptions have elevated the importance of sourcing strategy and manufacturing footprint decisions. Segmentation analysis underscores that success depends on deliberate alignment among drug type, formulation format, device selection, dosage approach, intended application, and end-user context.

For program leaders and investors, the imperative is clear: integrate device and formulation decisions early, build resilient and localized supply chains where warranted, and generate evidence that resonates with both regulators and payers by addressing mucosal and real-world effectiveness endpoints. Executional excellence across these domains will differentiate leaders who can translate intranasal scientific advances into accessible, effective products for patients and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in mucoadhesive polymer systems for prolonged intranasal drug residence time
  • 5.2. Utilization of aerosolized nanocarriers for enhanced brain-targeted delivery through the nasal route
  • 5.3. Integration of 3D printing techniques for personalized intranasal dosage form fabrication
  • 5.4. Clinical progress of live attenuated intranasal COVID-19 vaccines showing improved mucosal immunity
  • 5.5. Emerging intranasal migraine therapies leveraging rapid onset small molecule formulations
  • 5.6. Expansion of intranasal insulin sprays for neurodegenerative disease treatment in clinical trials
  • 5.7. Scaled manufacturing of dry powder nasal vaccines using advanced spray freeze drying technologies
  • 5.8. Collaboration between pharmaceutical and device manufacturers to optimize nasal spray delivery systems
  • 5.9. Adoption of real-time imaging techniques to monitor intranasal deposition and absorption profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intranasal Drug & Vaccine Delivery Market, by Drug Type

  • 8.1. Analgesics
    • 8.1.1. Non-opioids
    • 8.1.2. Opioids
  • 8.2. Antihistamines
  • 8.3. Steroids
  • 8.4. Vaccines
    • 8.4.1. Inactivated Vaccines
    • 8.4.2. Live Attenuated Vaccines
    • 8.4.3. mRNA-based Vaccine

9. Intranasal Drug & Vaccine Delivery Market, by Formulation Type

  • 9.1. Gel Formulations
  • 9.2. Liquid Formulations
  • 9.3. Powder Formulations

10. Intranasal Drug & Vaccine Delivery Market, by Device Type

  • 10.1. Atomizer
  • 10.2. Nasal Dropper
  • 10.3. Nasal Spray

11. Intranasal Drug & Vaccine Delivery Market, by Dosage

  • 11.1. Multi-dose
  • 11.2. Unit-dose

12. Intranasal Drug & Vaccine Delivery Market, by Application

  • 12.1. Allergy Treatment
  • 12.2. Hormone Replacement
  • 12.3. Neurological Conditions
  • 12.4. Pain Management
  • 12.5. Psychiatric Disorders
  • 12.6. Therapeutic Drug Delivery

13. Intranasal Drug & Vaccine Delivery Market, by End-User

  • 13.1. Homecare
  • 13.2. Hospitals & Clinics
  • 13.3. Research & Academic Institution

14. Intranasal Drug & Vaccine Delivery Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Intranasal Drug & Vaccine Delivery Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Intranasal Drug & Vaccine Delivery Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Altimmune, Inc.
    • 17.3.2. AptarGroup, Inc.
    • 17.3.3. AstraZeneca PLC
    • 17.3.4. Bausch Health Companies Inc.
    • 17.3.5. Bayer AG
    • 17.3.6. Becton, Dickinson, and Company
    • 17.3.7. Bharat Biotech Ltd.
    • 17.3.8. Boehringer Ingelheim International GmbH.
    • 17.3.9. Catalent, Inc
    • 17.3.10. DCA Design International Limited
    • 17.3.11. Emergent BioSolutions Inc.
    • 17.3.12. GlaxoSmithKline PLC
    • 17.3.13. Hovione Limited
    • 17.3.14. Impel Pharmaceuticals LLC.
    • 17.3.15. Indivior PLC
    • 17.3.16. Intersect ENT by Medtronic plc
    • 17.3.17. Intertek Group PLC
    • 17.3.18. Johnson & Johnson Services, Inc.
    • 17.3.19. Kindeva Drug Delivery L.P.
    • 17.3.20. Merck & Co., Inc.
    • 17.3.21. Neurelis, Inc.
    • 17.3.22. Novartis AG
    • 17.3.23. OptiNose, Inc.
    • 17.3.24. Pfizer Inc.
    • 17.3.25. Recipharm AB.
    • 17.3.26. Sanofi S.A.
    • 17.3.27. Teleflex Incorporated
    • 17.3.28. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. INTRANASAL DRUG & VACCINE DELIVERY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. INTRANASAL DRUG & VACCINE DELIVERY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 20